SRR612407
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.409
- INFLAMMATORY_RESPONSE+0.325
- IL2_STAT5_SIGNALING+0.305
- CHOLESTEROL_HOMEOSTASIS+0.292
- ALLOGRAFT_REJECTION+0.283
- HEME_METABOLISM+0.276
- INTERFERON_GAMMA_RESPONSE+0.274
- TNFA_SIGNALING_VIA_NFKB+0.264
- TGF_BETA_SIGNALING+0.260
- APICAL_SURFACE+0.256
Top 10 suppressed
- MYC_TARGETS_V1-0.408
- MYC_TARGETS_V2-0.408
- OXIDATIVE_PHOSPHORYLATION-0.401
- DNA_REPAIR-0.391
- E2F_TARGETS-0.377
- G2M_CHECKPOINT-0.267
- UNFOLDED_PROTEIN_RESPONSE-0.232
- HEDGEHOG_SIGNALING-0.181
- PANCREAS_BETA_CELLS-0.179
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.165
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1346813 | GTEX | — | 0.908 |
| 2 | SRR1340133 | GTEX | — | 0.892 |
| 3 | SRR613807 | GTEX | — | 0.882 |
| 4 | BS_Z7Y2466H | pilocytic astrocytoma | — | 0.879 |
| 5 | SRR665241 | GTEX | — | 0.879 |
| 6 | TCGA-CR-7394-01A-11R-2016-07 | — | — | 0.879 |
| 7 | BS_47SJZ3PH | low-grade glioma | — | 0.872 |
| 8 | SRR614443 | GTEX | — | 0.871 |
| 9 | BS_401R3KV0 | pilocytic astrocytoma | — | 0.860 |
| 10 | BS_BC936YNZ | pilocytic astrocytoma | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.409 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.325 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.305 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.292 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.283 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.276 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.274 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.264 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.256 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.252 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.251 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.248 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.242 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.238 | Inavolisib | — uncovered |
| COMPLEMENT | 0.238 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.209 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.208 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.205 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |